Download video

Dr. Venook: Would you consider another EGFR-directed therapy in this patient ?

19 views

Targeted Oncology

9 years ago

Dr. Venook: Would you consider another EGFR-directed therapy in this patient ?

Dr. Venook: Would you consider another EGFR-directed therapy in this patient ?

Dr. Venook: Would you consider another EGFR-directed therapy in this patient ?
0:40
Dr. Venook: Would you consider another EGFR-directed therapy in this patient ?
by Targeted Oncology
Dr. Venook: Would you consider an EGFR-directed therapy, does mutational status matter?
0:35
Dr. Venook: Would you consider an EGFR-directed therapy, does mutational status matter?
by Targeted Oncology
Dr. Venook: What are your choices for fourth-line treatment in this patient?
0:50
Dr. Venook: What are your choices for fourth-line treatment in this patient?
by Targeted Oncology
Dr. Venook: Should anti-angiogenesis therapy be continued in this patient?
0:31
Dr. Venook: Should anti-angiogenesis therapy be continued in this patient?
by Targeted Oncology
Dr. Venook Discusses the Future of Colorectal Cancer Treatment
0:48
Dr. Venook Discusses the Future of Colorectal Cancer Treatment
by OncLive
Dr. Venook on Advice for Oncologists Treating Patients With CRC
0:55
Dr. Venook on Advice for Oncologists Treating Patients With CRC
by OncLive
Dr. Venook on Looking Ahead at Treatment for CRC
1:03
Dr. Venook on Looking Ahead at Treatment for CRC
by OncLive
Dr. Venook on Evolving Treatment Strategies in CRC
1:59
Dr. Venook on Evolving Treatment Strategies in CRC
by OncLive
Угроза для человечества находится в Сибири? Срочное обращение - Эгон Чолакян
40:55
Угроза для человечества находится в Сибири? Срочное обращение - Эгон Чолакян
by TV Extra
Er schreibt nicht mehr, geht auf Distanz? Warte nicht, sondern mach DAS, um IHN anzuziehen!
9:47
Er schreibt nicht mehr, geht auf Distanz? Warte nicht, sondern mach DAS, um IHN anzuziehen!
by Roland Demian
Anti-Angiogenesis - Antiangiogenesis
2:26
Anti-Angiogenesis - Antiangiogenesis
by Kyle Thornthwaite
Dr. Venook Discusses the Results of the 80405 Trial
1:07
Dr. Venook Discusses the Results of the 80405 Trial
by OncLive
Dr. Venook : What second-line options are available to prolong survival?
0:47
Dr. Venook : What second-line options are available to prolong survival?
by Targeted Oncology
Dr. Venook on Important Factors for Treating Patients With CRC
1:57
Dr. Venook on Important Factors for Treating Patients With CRC
by OncLive
Dr. Venook Discusses the Approval of Ramucirumab Plus Paclitaxel
0:41
Dr. Venook Discusses the Approval of Ramucirumab Plus Paclitaxel
by OncLive
Dr. Alan Venook on Using Frailty Index \& Geriatric Assessments
0:37
Dr. Alan Venook on Using Frailty Index \& Geriatric Assessments
by OncLive
Dr. West on Emerging Changes in the Field of EGFR-Mutant NSCLC
0:59
Dr. West on Emerging Changes in the Field of EGFR-Mutant NSCLC
by OncLive
Dr. Alan Venook on Geographic Variations in the Therapies Used to Treat Cancer
1:26
Dr. Alan Venook on Geographic Variations in the Therapies Used to Treat Cancer
by OncLive
Unmet needs and future directions in the treating rare pancreatic cancers
1:45
Unmet needs and future directions in the treating rare pancreatic cancers
by VJOncology
Alan Venook, MD, explains how tumor sidedness affects therapeutic choice
1:54
Alan Venook, MD, explains how tumor sidedness affects therapeutic choice
by OBRoncology
Venook: What are the principal options to control metastatic disease ?
1:00
Venook: What are the principal options to control metastatic disease ?
by Targeted Oncology
Dr. Chung: What are your choices for fourth-line treatment in this patient with progressive disease?
2:42
Dr. Chung: What are your choices for fourth-line treatment in this patient with progressive disease?
by Targeted Oncology
Alan P. Venook, MD, on identifying subgroups of HCC patients that are likely to respond to therapy
0:52
Alan P. Venook, MD, on identifying subgroups of HCC patients that are likely to respond to therapy
by OBRoncology